<p>在当今快速变化且竞争激烈的商业世界中，投资者和行业爱好者仔细评估公司至关重要。本文将对制药行业的 <strong>辉瑞（NYSE: PFE）</strong> 进行全面的行业比较，评估其与主要竞争对手的表现。通过分析重要的财务指标、市场地位和增长前景，我们旨在为投资者提供有价值的见解，并揭示公司在行业中的表现。</p>
<h3>辉瑞背景</h3>
<p>辉瑞是全球最大的制药公司之一，年销售额约为 600 亿美元。虽然辉瑞历史上销售多种类型的医疗产品和化学品，但目前处方药和疫苗占据了大部分销售额。主要畅销产品包括肺炎球菌疫苗 Prevnar 13 和心脏病药物 Vyndaqel 和 Eliquis。辉瑞在全球范围内销售这些产品，国际销售占总销售额的 40%。在国际销售中，新兴市场是一个主要贡献者。</p>
<table>
<thead>
<tr>
<th><strong>公司</strong></th>
<th><strong>市盈率</strong></th>
<th><strong>市净率</strong></th>
<th><strong>市销率</strong></th>
<th><strong>股本回报率</strong></th>
<th><strong>息税折旧摊销前利润（十亿美元）</strong></th>
<th><strong>毛利润（十亿美元）</strong></th>
<th><strong>收入增长</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>辉瑞公司</td>
<td>14.56</td>
<td>1.53</td>
<td>2.28</td>
<td>3.9%</td>
<td>$5.65</td>
<td>$12.48</td>
<td>-5.91%</td>
</tr>
<tr>
<td>礼来公司</td>
<td>51.04</td>
<td>39.19</td>
<td>15.79</td>
<td>26.54%</td>
<td>$7.88</td>
<td>$14.59</td>
<td>53.87%</td>
</tr>
<tr>
<td>强生公司</td>
<td>20.32</td>
<td>6.39</td>
<td>5.54</td>
<td>6.53%</td>
<td>$9.52</td>
<td>$16.69</td>
<td>6.77%</td>
</tr>
<tr>
<td>阿斯利康公司</td>
<td>29.85</td>
<td>6.07</td>
<td>4.83</td>
<td>5.59%</td>
<td>$5.23</td>
<td>$12.39</td>
<td>11.99%</td>
</tr>
<tr>
<td>诺华公司</td>
<td>18.47</td>
<td>5.84</td>
<td>4.73</td>
<td>9.1%</td>
<td>$5.84</td>
<td>$10.82</td>
<td>9.0%</td>
</tr>
<tr>
<td>默克公司</td>
<td>13.12</td>
<td>4.75</td>
<td>3.89</td>
<td>11.47%</td>
<td>$8.23</td>
<td>$13.42</td>
<td>3.72%</td>
</tr>
<tr>
<td>诺和诺德公司</td>
<td>13.01</td>
<td>7.94</td>
<td>4.28</td>
<td>11.84%</td>
<td>$31.44</td>
<td>$57.07</td>
<td>5.14%</td>
</tr>
<tr>
<td>赛诺菲公司</td>
<td>15.63</td>
<td>1.36</td>
<td>2.19</td>
<td>3.91%</td>
<td>$4.2</td>
<td>$9.76</td>
<td>1.49%</td>
</tr>
<tr>
<td>布里斯托尔 - 迈尔斯斯奎布公司</td>
<td>18.03</td>
<td>5.88</td>
<td>2.27</td>
<td>12.23%</td>
<td>$4.61</td>
<td>$8.79</td>
<td>2.77%</td>
</tr>
<tr>
<td>GSK 公司</td>
<td>13.69</td>
<td>4.55</td>
<td>2.34</td>
<td>13.01%</td>
<td>$3.36</td>
<td>$6.29</td>
<td>6.68%</td>
</tr>
<tr>
<td>Zoetis 公司</td>
<td>20.58</td>
<td>9.98</td>
<td>5.81</td>
<td>13.9%</td>
<td>$1.07</td>
<td>$1.72</td>
<td>0.5%</td>
</tr>
<tr>
<td>武田药品工业公司</td>
<td>218.12</td>
<td>0.99</td>
<td>1.63</td>
<td>-0.17%</td>
<td>$316.47</td>
<td>$732.74</td>
<td>-5.38%</td>
</tr>
<tr>
<td>Teva 制药工业公司</td>
<td>49.28</td>
<td>4.76</td>
<td>2.07</td>
<td>6.15%</td>
<td>$1.1</td>
<td>$2.3</td>
<td>3.42%</td>
</tr>
<tr>
<td>Dr Reddy's 实验室公司</td>
<td>17.99</td>
<td>2.94</td>
<td>3.08</td>
<td>4.06%</td>
<td>$24.31</td>
<td>$48.14</td>
<td>9.84%</td>
</tr>
<tr>
<td>Elanco 动物健康公司</td>
<td>315.43</td>
<td>1.63</td>
<td>2.41</td>
<td>-0.5%</td>
<td>$0.18</td>
<td>$0.61</td>
<td>10.39%</td>
</tr>
<tr>
<td>Corcept 治疗公司</td>
<td>94.57</td>
<td>13.70</td>
<td>13.30</td>
<td>3.05%</td>
<td>$0.01</td>
<td>$0.2</td>
<td>13.75%</td>
</tr>
<tr>
<td><strong>平均</strong></td>
<td><strong>60.61</strong></td>
<td><strong>7.73</strong></td>
<td><strong>4.94</strong></td>
<td><strong>8.45%</strong></td>
<td><strong>$28.23</strong></td>
<td><strong>$62.37</strong></td>
<td><strong>8.93%</strong></td>
</tr>
</tbody>
</table>
<p>通过对辉瑞进行深入分析，我们可以识别出以下趋势：</p>
<ul>
<li>该股票的市盈率为 14.56，低于行业平均水平 0.24 倍，暗示市场参与者可能认为其具有潜在价值。</li>
</ul>
<ul>
<li>考虑到市净率为 1.53，远低于行业平均水平 0.2 倍，该股票可能在其账面价值基础上被低估。</li>
</ul>
<ul>
<li>该公司的市销率相对较低，为 2.28，只有行业平均水平的 0.46 倍，可能被认为在销售表现上被低估。</li>
</ul>
<ul>
<li>公司的股本回报率（ROE）为 3.9%，低于行业平均水平 4.55%。这表明在利用股本产生利润方面可能存在效率低下，可能与多种因素有关。</li>
</ul>
<ul>
<li>公司的息税折旧摊销前利润（EBITDA）为 56.5 亿美元，低于行业平均水平 0.2 倍。这可能表明盈利能力较低或面临财务挑战。</li>
</ul>
<ul>
<li>公司的毛利润为 124.8 亿美元，低于行业平均水平 0.2 倍。这可能表明在扣除生产成本后收入较低。</li>
</ul>
<ul>
<li>收入增长为-5.91%，远低于行业平均水平 8.93%，公司在销售扩张方面正经历显著放缓。</li>
</ul>
<h3>债务与股本比率</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766070063_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="债务与股本" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766070063_0.png"/></p>
<p>债务与股本比率（D/E）是一个衡量公司相对于其净资产价值所承担债务水平的指标。</p>
<p>在行业比较中考虑债务与股本比率，可以简洁地评估公司的财务健康状况和风险特征，帮助做出明智的决策。</p>
<p>通过分析辉瑞与其在债务与股本比率方面的前四大同行的关系，可以得出以下见解：</p>
<ul>
<li>辉瑞在该行业的前四大同行中展现出更强的财务状况。</li>
</ul>
<ul>
<li>公司的债务与股本比率为 0.66，低于同行，表明公司对债务融资的依赖较小，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极信号。</li>
</ul>
<h3>关键要点</h3>
<p>对于辉瑞而言，其市盈率、市净率和市销率均低于制药行业的同行，表明可能被低估。然而，辉瑞的低 ROE 表明其盈利能力低于行业同行。此外，低 EBITDA、毛利润和收入增长进一步突显了在与竞争对手相比时，产生利润和收入增长的潜在挑战。</p>
<p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>

辉瑞

<p>本文对辉瑞在制药行业中的竞争对手进行了评估，分析了市盈率（PE）、市净率（PB）、市销率（PS）、股本回报率（ROE）、息税折旧摊销前利润（EBITDA）和收入增长等财务指标。辉瑞显示出潜在的低估，但在盈利能力和收入增长方面面临挑战。与主要竞争对手相比，辉瑞的财务状况更强，债务与股本比率较低，表明其对债务融资的依赖程度较低。该分析为投资者提供了有关辉瑞市场地位和财务健康状况的见解</p>

<p>In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating <strong>Pfizer (NYSE: PFE)</strong> against its key competitors in the Pharmaceuticals industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.</p>
<div class="lb-trans"><p>在当今快速变化且竞争激烈的商业世界中，投资者和行业爱好者仔细评估公司至关重要。本文将对制药行业的 <strong>辉瑞（NYSE: PFE）</strong> 进行全面的行业比较，评估其与主要竞争对手的表现。通过分析重要的财务指标、市场地位和增长前景，我们旨在为投资者提供有价值的见解，并揭示公司在行业中的表现。</p>
</div><h3>Pfizer Background</h3>
<div class="lb-trans"><h3>辉瑞背景</h3>
</div><p>Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.</p>
<div class="lb-trans"><p>辉瑞是全球最大的制药公司之一，年销售额约为 600 亿美元。虽然辉瑞历史上销售多种类型的医疗产品和化学品，但目前处方药和疫苗占据了大部分销售额。主要畅销产品包括肺炎球菌疫苗 Prevnar 13 和心脏病药物 Vyndaqel 和 Eliquis。辉瑞在全球范围内销售这些产品，国际销售占总销售额的 40%。在国际销售中，新兴市场是一个主要贡献者。</p>
</div><table>
<thead>
<tr>
<th><strong>Company</strong></th>
<th><strong>P/E</strong></th>
<th><strong>P/B</strong></th>
<th><strong>P/S</strong></th>
<th><strong>ROE</strong></th>
<th><strong>EBITDA (in billions)</strong></th>
<th><strong>Gross Profit (in billions)</strong></th>
<th><strong>Revenue Growth</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Inc</td>
<td>14.56</td>
<td>1.53</td>
<td>2.28</td>
<td>3.9%</td>
<td>$5.65</td>
<td>$12.48</td>
<td>-5.91%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>51.04</td>
<td>39.19</td>
<td>15.79</td>
<td>26.54%</td>
<td>$7.88</td>
<td>$14.59</td>
<td>53.87%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>20.32</td>
<td>6.39</td>
<td>5.54</td>
<td>6.53%</td>
<td>$9.52</td>
<td>$16.69</td>
<td>6.77%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>29.85</td>
<td>6.07</td>
<td>4.83</td>
<td>5.59%</td>
<td>$5.23</td>
<td>$12.39</td>
<td>11.99%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>18.47</td>
<td>5.84</td>
<td>4.73</td>
<td>9.1%</td>
<td>$5.84</td>
<td>$10.82</td>
<td>9.0%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>13.12</td>
<td>4.75</td>
<td>3.89</td>
<td>11.47%</td>
<td>$8.23</td>
<td>$13.42</td>
<td>3.72%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>13.01</td>
<td>7.94</td>
<td>4.28</td>
<td>11.84%</td>
<td>$31.44</td>
<td>$57.07</td>
<td>5.14%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>15.63</td>
<td>1.36</td>
<td>2.19</td>
<td>3.91%</td>
<td>$4.2</td>
<td>$9.76</td>
<td>1.49%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co</td>
<td>18.03</td>
<td>5.88</td>
<td>2.27</td>
<td>12.23%</td>
<td>$4.61</td>
<td>$8.79</td>
<td>2.77%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>13.69</td>
<td>4.55</td>
<td>2.34</td>
<td>13.01%</td>
<td>$3.36</td>
<td>$6.29</td>
<td>6.68%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>20.58</td>
<td>9.98</td>
<td>5.81</td>
<td>13.9%</td>
<td>$1.07</td>
<td>$1.72</td>
<td>0.5%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>218.12</td>
<td>0.99</td>
<td>1.63</td>
<td>-0.17%</td>
<td>$316.47</td>
<td>$732.74</td>
<td>-5.38%</td>
</tr>
<tr>
<td>Teva Pharmaceutical Industries Ltd</td>
<td>49.28</td>
<td>4.76</td>
<td>2.07</td>
<td>6.15%</td>
<td>$1.1</td>
<td>$2.3</td>
<td>3.42%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>17.99</td>
<td>2.94</td>
<td>3.08</td>
<td>4.06%</td>
<td>$24.31</td>
<td>$48.14</td>
<td>9.84%</td>
</tr>
<tr>
<td>Elanco Animal Health Inc</td>
<td>315.43</td>
<td>1.63</td>
<td>2.41</td>
<td>-0.5%</td>
<td>$0.18</td>
<td>$0.61</td>
<td>10.39%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>94.57</td>
<td>13.70</td>
<td>13.30</td>
<td>3.05%</td>
<td>$0.01</td>
<td>$0.2</td>
<td>13.75%</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>60.61</strong></td>
<td><strong>7.73</strong></td>
<td><strong>4.94</strong></td>
<td><strong>8.45%</strong></td>
<td><strong>$28.23</strong></td>
<td><strong>$62.37</strong></td>
<td><strong>8.93%</strong></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>公司</strong></th>
<th><strong>市盈率</strong></th>
<th><strong>市净率</strong></th>
<th><strong>市销率</strong></th>
<th><strong>股本回报率</strong></th>
<th><strong>息税折旧摊销前利润（十亿美元）</strong></th>
<th><strong>毛利润（十亿美元）</strong></th>
<th><strong>收入增长</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>辉瑞公司</td>
<td>14.56</td>
<td>1.53</td>
<td>2.28</td>
<td>3.9%</td>
<td>$5.65</td>
<td>$12.48</td>
<td>-5.91%</td>
</tr>
<tr>
<td>礼来公司</td>
<td>51.04</td>
<td>39.19</td>
<td>15.79</td>
<td>26.54%</td>
<td>$7.88</td>
<td>$14.59</td>
<td>53.87%</td>
</tr>
<tr>
<td>强生公司</td>
<td>20.32</td>
<td>6.39</td>
<td>5.54</td>
<td>6.53%</td>
<td>$9.52</td>
<td>$16.69</td>
<td>6.77%</td>
</tr>
<tr>
<td>阿斯利康公司</td>
<td>29.85</td>
<td>6.07</td>
<td>4.83</td>
<td>5.59%</td>
<td>$5.23</td>
<td>$12.39</td>
<td>11.99%</td>
</tr>
<tr>
<td>诺华公司</td>
<td>18.47</td>
<td>5.84</td>
<td>4.73</td>
<td>9.1%</td>
<td>$5.84</td>
<td>$10.82</td>
<td>9.0%</td>
</tr>
<tr>
<td>默克公司</td>
<td>13.12</td>
<td>4.75</td>
<td>3.89</td>
<td>11.47%</td>
<td>$8.23</td>
<td>$13.42</td>
<td>3.72%</td>
</tr>
<tr>
<td>诺和诺德公司</td>
<td>13.01</td>
<td>7.94</td>
<td>4.28</td>
<td>11.84%</td>
<td>$31.44</td>
<td>$57.07</td>
<td>5.14%</td>
</tr>
<tr>
<td>赛诺菲公司</td>
<td>15.63</td>
<td>1.36</td>
<td>2.19</td>
<td>3.91%</td>
<td>$4.2</td>
<td>$9.76</td>
<td>1.49%</td>
</tr>
<tr>
<td>布里斯托尔 - 迈尔斯斯奎布公司</td>
<td>18.03</td>
<td>5.88</td>
<td>2.27</td>
<td>12.23%</td>
<td>$4.61</td>
<td>$8.79</td>
<td>2.77%</td>
</tr>
<tr>
<td>GSK 公司</td>
<td>13.69</td>
<td>4.55</td>
<td>2.34</td>
<td>13.01%</td>
<td>$3.36</td>
<td>$6.29</td>
<td>6.68%</td>
</tr>
<tr>
<td>Zoetis 公司</td>
<td>20.58</td>
<td>9.98</td>
<td>5.81</td>
<td>13.9%</td>
<td>$1.07</td>
<td>$1.72</td>
<td>0.5%</td>
</tr>
<tr>
<td>武田药品工业公司</td>
<td>218.12</td>
<td>0.99</td>
<td>1.63</td>
<td>-0.17%</td>
<td>$316.47</td>
<td>$732.74</td>
<td>-5.38%</td>
</tr>
<tr>
<td>Teva 制药工业公司</td>
<td>49.28</td>
<td>4.76</td>
<td>2.07</td>
<td>6.15%</td>
<td>$1.1</td>
<td>$2.3</td>
<td>3.42%</td>
</tr>
<tr>
<td>Dr Reddy's 实验室公司</td>
<td>17.99</td>
<td>2.94</td>
<td>3.08</td>
<td>4.06%</td>
<td>$24.31</td>
<td>$48.14</td>
<td>9.84%</td>
</tr>
<tr>
<td>Elanco 动物健康公司</td>
<td>315.43</td>
<td>1.63</td>
<td>2.41</td>
<td>-0.5%</td>
<td>$0.18</td>
<td>$0.61</td>
<td>10.39%</td>
</tr>
<tr>
<td>Corcept 治疗公司</td>
<td>94.57</td>
<td>13.70</td>
<td>13.30</td>
<td>3.05%</td>
<td>$0.01</td>
<td>$0.2</td>
<td>13.75%</td>
</tr>
<tr>
<td><strong>平均</strong></td>
<td><strong>60.61</strong></td>
<td><strong>7.73</strong></td>
<td><strong>4.94</strong></td>
<td><strong>8.45%</strong></td>
<td><strong>$28.23</strong></td>
<td><strong>$62.37</strong></td>
<td><strong>8.93%</strong></td>
</tr>
</tbody>
</table>
</div><p>By conducting an in-depth analysis of Pfizer, we can identify the following trends:</p>
<div class="lb-trans"><p>通过对辉瑞进行深入分析，我们可以识别出以下趋势：</p>
</div><ul>
<li>The stock's Price to Earnings ratio of 14.56 is lower than the industry average by 0.24x, suggesting potential value in the eyes of market participants.</li>
</ul>
<div class="lb-trans"><ul>
<li>该股票的市盈率为 14.56，低于行业平均水平 0.24 倍，暗示市场参与者可能认为其具有潜在价值。</li>
</ul>
</div><ul>
<li>Considering a Price to Book ratio of 1.53, which is well below the industry average by 0.2x, the stock may be undervalued based on its book value compared to its peers.</li>
</ul>
<div class="lb-trans"><ul>
<li>考虑到市净率为 1.53，远低于行业平均水平 0.2 倍，该股票可能在其账面价值基础上被低估。</li>
</ul>
</div><ul>
<li>With a relatively low Price to Sales ratio of 2.28, which is 0.46x the industry average, the stock might be considered undervalued based on sales performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>该公司的市销率相对较低，为 2.28，只有行业平均水平的 0.46 倍，可能被认为在销售表现上被低估。</li>
</ul>
</div><ul>
<li>The company has a lower Return on Equity (ROE) of 3.9%, which is 4.55% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司的股本回报率（ROE）为 3.9%，低于行业平均水平 4.55%。这表明在利用股本产生利润方面可能存在效率低下，可能与多种因素有关。</li>
</ul>
</div><ul>
<li>The company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.65 Billion, which is 0.2x below the industry average. This potentially indicates lower profitability or financial challenges.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司的息税折旧摊销前利润（EBITDA）为 56.5 亿美元，低于行业平均水平 0.2 倍。这可能表明盈利能力较低或面临财务挑战。</li>
</ul>
</div><ul>
<li>The company has lower gross profit of $12.48 Billion, which indicates 0.2x below the industry average. This potentially indicates lower revenue after accounting for production costs.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司的毛利润为 124.8 亿美元，低于行业平均水平 0.2 倍。这可能表明在扣除生产成本后收入较低。</li>
</ul>
</div><ul>
<li>With a revenue growth of -5.91%, which is much lower than the industry average of 8.93%, the company is experiencing a notable slowdown in sales expansion.</li>
</ul>
<div class="lb-trans"><ul>
<li>收入增长为-5.91%，远低于行业平均水平 8.93%，公司在销售扩张方面正经历显著放缓。</li>
</ul>
</div><h3>Debt To Equity Ratio</h3>
<div class="lb-trans"><h3>债务与股本比率</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766070063_0.png" alt="debt to equity" original-src="https://www.benzinga.com/files/images/story/2025/1766070063_0.png"/></p>
<p>The debt-to-equity (D/E) ratio is a measure that indicates the level of debt a company has taken on relative to the value of its assets net of liabilities.</p>
<div class="lb-trans"><p>债务与股本比率（D/E）是一个衡量公司相对于其净资产价值所承担债务水平的指标。</p>
</div><p>Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.</p>
<div class="lb-trans"><p>在行业比较中考虑债务与股本比率，可以简洁地评估公司的财务健康状况和风险特征，帮助做出明智的决策。</p>
</div><p>By analyzing Pfizer in relation to its top 4 peers based on the Debt-to-Equity ratio, the following insights can be derived:</p>
<div class="lb-trans"><p>通过分析辉瑞与其在债务与股本比率方面的前四大同行的关系，可以得出以下见解：</p>
</div><ul>
<li>Pfizer demonstrates a stronger financial position compared to its top 4 peers in the sector.</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞在该行业的前四大同行中展现出更强的财务状况。</li>
</ul>
</div><ul>
<li>With a lower debt-to-equity ratio of 0.66, the company relies less on debt financing and maintains a healthier balance between debt and equity, which can be viewed positively by investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>公司的债务与股本比率为 0.66，低于同行，表明公司对债务融资的依赖较小，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极信号。</li>
</ul>
</div><h3>Key Takeaways</h3>
<div class="lb-trans"><h3>关键要点</h3>
</div><p>For Pfizer, the PE, PB, and PS ratios are all low compared to its peers in the Pharmaceuticals industry, indicating potential undervaluation. However, Pfizer's low ROE suggests lower profitability compared to industry peers. Additionally, the low EBITDA, gross profit, and revenue growth further highlight potential challenges in generating profits and revenue growth compared to its competitors.</p>
<div class="lb-trans"><p>对于辉瑞而言，其市盈率、市净率和市销率均低于制药行业的同行，表明可能被低估。然而，辉瑞的低 ROE 表明其盈利能力低于行业同行。此外，低 EBITDA、毛利润和收入增长进一步突显了在与竞争对手相比时，产生利润和收入增长的潜在挑战。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>
</div>

Industry Comparison: Evaluating Pfizer Against Competitors In Pharmaceuticals Industry

- 辉瑞在制药行业的市盈率、净资产收益率等指标低于行业平均水平。  
- 辉瑞的收入增长为负，表明销售扩展放缓，面临盈利挑战。  
- 相对较低的负债比率显示辉瑞的财务状况较同业竞争者更为稳健。

行业比较：评估辉瑞在制药行业中与竞争对手的表现